Cardiac Ischemia in the Diabetic Patient with End-Stage Renal Disease

Annual Report 1998, Vol 1. Dialysis and Renal Transplantation, Canadian Organ Replacement Register. Ottawa: Canadian Institute for Health Information, June, 1998.

United States Renal Data System. USRDS 1998 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, April, 1998.

Churchill D.N. , Thorpe K.E. , Teehan B.P. for the CANUSA Peritoneal Dialysis Study Group. Semin Dial 1997; 10: 215–18.

de Lemos J.A. , Hills L.D. Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis. J Am Soc Nephrol 1996; 10: 2044–54.

Mall G. , Huther W. , Schneider J. , Lundin P. , Ritz E. Diffuse intramyocardiocytic fibrosis in uremic patients. Nephrol Dial Transplant 1990; 5: 39–44.

Amann K. , Breitbach M. , Ritz E. , Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 1998; 9: 1018–22.

Amann K. , Kronenberg G. , Gelhen F. , Wessels S. , Orth S. , Minter K. Cardiac remodelling in experimental renal failure — an immunohistochemical study. Nephrol Dial Transplant 1998; 13: 1958–66.

Boudreau R.J. , Strony J.T. , duCret R.P. , Kuni C.C. , Wang Y. , Wilson R.F. Perfusion thallium imaging of type 1 diabetes patients with end-stage renal disease: comparison of oral and intravenous dipyridamole administration. Radiology 1990; 175: 103–5.

Reis G. , Marcovitz P.A. , Leichtman A.B. , Merion R.M. , Fay W. P. , Werns S W. Usefulness of dobutamine stress echocardiography in detecting coronary artery disease in end-stage renal failure. Am J Cardiol 1995; 75: 707–10.

Manske C.L. , Wang Y. , Rector T. , Wilson R.F. , White C.W. Coronary revascularization in insulin-dependent diabetic patients with chronic renal failure. Lancet 1992; 340: 998–1002.

Rinehart A.L. , Herzog C.A. , Collins A.J. , Flack J.M. , Ma J.Z. , Opsahi J.A. A comparison of coronary angioplasty and coronary bypass grafting in chronic dialysis patients. Am J Kidney Dis 1995; 25: 281–90.

Leypoldt J.K. , Cheung A.K. , Carroll C.E. , Stannard D.C. , Pereira B.J.G. , Agodoa L.Y. Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Am J Kidney Dis 1999; 33: 349–55.

Cannella G. , Paoletti E. , Delfino R. , Peloso G. , Molinari S. , Traverso G.B. Regression of left ventricular hypertrophy in hypertensive dialyzed patients on long-term antihypertensive therapy. Kidney Int 1993; 44: 881–6.

Charra B. , Calemard E. , Ruffet M. , Chazot C. , Terrat JCVT , Laurent G. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41: 1286–91.

Diabetes Control and Complications Trial Research Group (DCCT), The effect of intensive treatment of diabetes on the development and progression of complications in insulin dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86.

Pyorala K. , Pederson T.R. , Kjeksus J. , Faergeman O. , Olsson A.G. , Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a sub-group analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614–20.

Fried L. , Hutchison A. , Stegmayr B. , Pritchard S. , Bargman J.M. Recommendations for the treatment of lipid disorders in patients on peritoneal dialysis. Perit Dial Int 1999; 19: 7–16.

Arensen E. , Refsum H. , Bonaa K.H. , Uleland P.M. , Forde O.H. , Nordrehaug J.E. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24: 704–9.

Bostom A.G. , Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52: 10–20.

Sawicki P T. Mortality in diabetic nephropathy: the importance of the QT interval. Nephrol Dial Transplant 1996; 11: 1514–15.

Schwartz P.J. Idiopathic long QT syndrome. Progress and questions. Am Heart J 1985; 2: 399–411.

NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. New York: National Kidney Foundation, 1997: 24–8.

Besarab A. , Bolton W.K. , Browne J.K. , Egrie J.C. , Nissensen A.R. , Okamoto D.M. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoietin. N Engl J Med 1998; 339: 584–90.

Wakeem M. , Zimmerman S.W. Association between human recombinant EPO and peripheral vascular disease in diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 1998; 32: 488.

Meltzer S. , Leiter L. , Daneman D. , Gerstein H.C. , Lau D. , Ludwig S. Steering and Expert Committees: 1998 clinical practice guidelines for the management of diabetes in Canada. Can Med Assoc J 1998; 159(Suppl 8): S1–29.

Canadian Association of Nephrology clinical practice guidelines for treatment of patients with chronic renal failure. J Am Soc Nephrol 1999; 10(Suppl 13): S287–319.